Abacus Life Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abacus Life Inc reports robust Q3 performance and eyes growth

Abacus Life Inc delivered strong financial results, showcased program advancements, and expanded its asset base through strategic acquisitions.
The company's focus on innovation, partnerships, and financial strength positions it well for future growth and market expansion.
Challenges in integration, competition, and capital management exist but can be addressed through strategic planning and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abacus Life, Inc. is an integrated alternative asset manager, which engages in the business of investing in force life insurance products. The firm is involved in purchasing outstanding life insurance policies to connect buyers and sellers through an origination process. It operates through the following segments: Portfolio Servicing, Active Management, and Originations. The Portfolio Servicing segment offers policy services to customers on a contract basis. The Active Management segment is involved in buying, selling, and trading policies and maintaining policies through to death benefit. The Origination segment originates life insurance policy settlement contracts as a licensed life settlement provider on behalf of third-party institutional investors interested in investing in the life settlement asset class. The company was founded by Matthew Ganovsky, Kevin Scott Kirby, and Todd Sean McNealy on May 22, 2020 and is headquartered in Orlando, FL.

Abacus Life, Inc. (ABL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Abacus Life, Inc. (ABL) Upgraded to Strong Buy: Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 86.3% in Abacus Life, Inc. (ABL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Abacus Life, Inc. (ABL) Could Surge 86.27%: Read This Before Placing a Bet

ORLANDO, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announced it has completed the acquisition of FCF Advisors (“FCF”), a New York-based asset manager and index provider specializing in free cash flow-focused investment strategies. The acquisition of FCF, which currently has approximately $850 million in assets under management, constitutes a significant milestone in Abacus' ongoing expansion of ABL Wealth and its suite of products.

Abacus Life Completes Acquisition of FCF Advisors

ORLANDO, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announced it has completed the acquisition of Carlisle Management Company S.C.A. (“Carlisle”), a leading Luxembourg-based investment fund manager in the life settlement space with over U.S. $2 billion in assets under management. The Carlisle acquisition marks a key milestone in Abacus's stated strategy to drive long-term growth and diversify its value proposition through expanded global alternative asset-management offerings.

Abacus Life Completes Acquisition of Carlisle Management Company S.C.A.

ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, announced it has received regulatory non-objection from the Luxembourg Commission de Surveillance du Secteur Financier (“CSSF”) for the acquisition of Carlisle Management Company S.C.A. (“Carlisle”), a leading Luxembourg-based investment fund manager in the life settlement space.

Abacus Life Targets Close of the Acquisition of Carlisle Management Company S.C.A. for December 2, 2024 with Receipt of Regulatory Non-Objection

ORLANDO, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced the closing of its oversubscribed underwritten public offering of 12,500,000 shares of its common stock, consisting of 10,000,000 shares of its common stock sold by the Company and 2,500,000 shares of common stock sold by certain stockholders of the Company (the “Selling Stockholders”) at the public offering price of $8.00 per share. The gross proceeds raised in the offering, before underwriting discounts and commissions and estimated expenses of the offering, were approximately $100 million, of which approximately $80 million was raised in the primary offering by the Company and approximately $20 million was paid in connection with the sale of shares by the Selling Stockholders.

Abacus Life Announces Closing of Public Offering of 12,500,000 Shares of Common Stock

Abacus Life, Inc. NASDAQ: ABL is a global alternative asset manager specializing in a unique niche within the financial markets. The company acquires and manages life insurance policies.

Abacus Life's CEO on Cracking the Code of Longevity Returns

ORLANDO, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock, including 10,000,000 shares of common stock being offered by the Company and 2,500,000 shares of common stock being offered by certain stockholders of the Company (the “Selling Stockholders”), at a price to the public of $8.00 per share. In connection with the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock from the Company and up to an additional 375,000 shares of common stock from the Selling Stockholders at the public offering price. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $100 million, excluding any exercise of the underwriters' option to purchase additional shares.

Abacus Life Announces Pricing of Public Offering of Common Stock

ORLANDO, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in leveraging longevity and actuarial technology to offer uncorrelated investment opportunities, today announced the commencement of an underwritten public offering of 12,500,000 shares of its common stock, including 10,000,000 shares of common stock to be sold by the Company and 2,500,000 to be sold by certain stockholders of the Company (the “Selling Stockholders”). The Company and the Selling Stockholders also expect to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock from the Company and up to an additional 375,000 shares of common stock from the Selling Stockholders.

Abacus Life Announces Proposed Public Offering of Common Stock

The average of price targets set by Wall Street analysts indicates a potential upside of 59.5% in Abacus Life, Inc. (ABL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Abacus Life, Inc. (ABL) Could Rally 59.48%: Here's is How to Trade

Abacus Life, Inc. (NASDAQ:ABL ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Robert Phillips – Senior Vice President- Investor Relations and Corporate Affairs Jay Jackson – Chairman and Chief Executive Officer Bill McCauley – Chief Financial Officer Conference Call Participants Crispin Love – Piper Sandler Andrew Kligerman – TD Cowen Mike Grondahl – Northland Securities Operator Good day, ladies and gentlemen, and thank you for standing by. At this time all participants are in a listen-only mode.

Abacus Life, Inc. (ABL) Q3 2024 Earnings Call Transcript

Abacus Life, Inc. (ABL) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.01 per share a year ago.

Abacus Life, Inc. (ABL) Surpasses Q3 Earnings and Revenue Estimates

- Delivered Continued Revenue and Profitability Growth While Executing on Strategic Initiatives - - Third Quarter 2024 Total Revenue Grows 33% Year-over-Year to $28.1 Million - - Due to Non-Cash Increase in Warrant Liability of $8.7M; GAAP Net Loss of $5.1M - - Adjusted Net Income Grows 65% Year-over-Year to $14.9 Million - - Adjusted EBITDA Grows 54% Year-over-Year to $16.7 Million - ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today reported results for the third quarter ended September 30, 2024.

Abacus Life Reports Third Quarter 2024 Results

Abacus Life, Inc. (ABL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abacus Life, Inc. (ABL) Earnings Expected to Grow: Should You Buy?

VictoryShares US Small Cap High Div Volatility Wtd ETF

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #SMBs--Cambridge Savings Bank has provided a new credit facility to Fabrizia Spirits, a leading citrus spirits manufacturer in the United States.

Cambridge Savings Bank Extends New Credit Facility to Accelerate Growth for Fabrizia Spirits

ORLANDO, Fla., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial products, today announced it will release its Third Quarter 2024 financial results after the market closes on Thursday, November 7, 2024.

Abacus Life to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Does Abacus Life, Inc. (ABL) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Abacus Life, Inc. (ABL) a Strong Momentum Stock: Buy Now?

Mission Produce

Erie Indemnity

Sprouts Farmers Markets

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. ERIE, SFM, AVO & ABL are well-poised to gain.

Buy 4 Low-Beta Stocks & Forget About Volatility: ERIE, SFM, AVO, ABL

Abacus Life, Inc. (ABL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in Abacus Life, Inc. (ABL): Can Its 5.4% Jump Turn into More Strength?

The mean of analysts' price targets for Abacus Life, Inc. (ABL) points to a 34.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Abacus Life, Inc. (ABL) Have the Potential to Rally 34.62% as Wall Street Analysts Expect?

ORLANDO, Fla., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial products, today announced that its popular Abacus Policy Value Calculator, which recently launched its newest generation, has surpassed 150,000 individual submissions from insureds, totaling more than $87 billion in face value.

Abacus Life Policy Value Calculator Surpasses Milestone of 150,000 Policy Valuations

ORLANDO, Fla., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial products, today announced that Corey McLaren has joined Abacus as Managing Director, Capital Markets.

Corey McLaren Joins Abacus Life (ABL) as Managing Director, Capital Markets

Abacus Life, Inc. (ABL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Abacus Life, Inc. (ABL) Run Higher on Rising Earnings Estimates?

The consensus price target hints at a 32.7% upside potential for Abacus Life, Inc. (ABL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 32.72% Upside in Abacus Life, Inc. (ABL): Here's What You Should Know

ORLANDO, Fla and NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, and Lorisco Life LLC (“Lorisco”), a health prediction company using modern proteomics and machine learning to accurately forecast health events, today announced a new partnership and product launch to revolutionize longevity-based health prediction and actuarial technology.

News for Abacus Life Inc Stock (ABL)